PARP1 and cancer: Cancers that harbor DDR mutations might also benefit from targeting multiple DDR components: for example, inhibition of ATR after PARP inhibitor therapy can overcome PARP inhibitor resistance in tumors with a BRCA-mutant genetic background [140].